CA2974369A1 - Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing - Google Patents

Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing Download PDF

Info

Publication number
CA2974369A1
CA2974369A1 CA2974369A CA2974369A CA2974369A1 CA 2974369 A1 CA2974369 A1 CA 2974369A1 CA 2974369 A CA2974369 A CA 2974369A CA 2974369 A CA2974369 A CA 2974369A CA 2974369 A1 CA2974369 A1 CA 2974369A1
Authority
CA
Canada
Prior art keywords
mice
net
pad4
inhibitor
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2974369A
Other languages
English (en)
French (fr)
Inventor
Denisa D. Wagner
Siu Ling WONG
Luise ERPENBECK
Kimberly Lindsay MARTINOD
Jorn Thilo Witsch
Alexander SAVCHENKO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of CA2974369A1 publication Critical patent/CA2974369A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2974369A 2015-01-20 2016-01-19 Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing Abandoned CA2974369A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105342P 2015-01-20 2015-01-20
US62/105,342 2015-01-20
PCT/US2016/013847 WO2016118476A1 (en) 2015-01-20 2016-01-19 Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing

Publications (1)

Publication Number Publication Date
CA2974369A1 true CA2974369A1 (en) 2016-07-28

Family

ID=56417634

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2974369A Abandoned CA2974369A1 (en) 2015-01-20 2016-01-19 Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing

Country Status (5)

Country Link
US (3) US11400139B2 (enExample)
EP (2) EP3247386A4 (enExample)
JP (1) JP2018503685A (enExample)
CA (1) CA2974369A1 (enExample)
WO (1) WO2016118476A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
KR102806169B1 (ko) 2017-08-18 2025-05-13 뉴트롤리스 인코포레이티드 조작된 dnase 효소 및 치료에의 사용
EP3761971A4 (en) 2018-03-09 2021-11-10 The University of Memphis Research Foundation FLAMMATION INHIBITION COMPOSITIONS AND METHODS
WO2020006389A1 (en) * 2018-06-29 2020-01-02 Viktor Veniaminovich Tets Compositions for modulating gut microbiota
JP7657412B2 (ja) * 2019-09-06 2025-04-07 コンセホ、ナシオナル、デ、インベスティガシオネス、シエンティフィカス、イェ、テクニカス 局所創傷処置用の医薬組成物
GB202012326D0 (en) * 2020-08-07 2020-09-23 Citryll B V Diagnostic
CN113358872B (zh) * 2021-06-03 2022-10-21 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于评估肿瘤免疫治疗疗效的标志物组及系统

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6919320B1 (en) * 1987-10-28 2005-07-19 Wellstat Therapeutics Corporation Pharmaceutical compositions containing deoxyribonucleosides for wound healing
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
DE68929551T2 (de) 1988-12-23 2008-03-06 Genentech, Inc., South San Francisco Menschliche DNase
DE3903672C1 (enExample) 1989-02-08 1990-02-01 Lohmann Gmbh & Co Kg
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5540935A (en) 1993-12-06 1996-07-30 Nof Corporation Reactive vesicle and functional substance-fixed vesicle
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
US5539878A (en) 1995-06-16 1996-07-23 Elonex Technologies, Inc. Parallel testing of CPU cache and instruction units
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
AU731909B2 (en) 1997-07-01 2001-04-05 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
EP1156812A4 (en) 1999-02-23 2004-09-29 Isis Pharmaceuticals Inc MULTIPARTICULAR FORMULATION
IT1318539B1 (it) 2000-05-26 2003-08-27 Italfarmaco Spa Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
US7063860B2 (en) 2001-08-13 2006-06-20 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
CN1914168A (zh) 2004-02-04 2007-02-14 公立大学法人横浜市立大学 肽基精氨酸脱亚胺酶4抑制剂
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2007056389A2 (en) 2005-11-07 2007-05-18 University Of South Carolina Synthesis and use of novel inhibitors and inactivators of protein arginine deiminases
WO2009121183A1 (en) 2008-04-03 2009-10-08 Kane Biotech Inc. Dispersinbtm, 5-fluorouracil, deoxyribonuclease i and proteinase k-based antibiofilm compositions and uses thereof
KR20110063731A (ko) 2008-06-16 2011-06-14 치라릭스 비.브이. 펩티딜아르기닌 디이미나아제(ｐａｄ) 억제제
US9642822B2 (en) * 2011-05-27 2017-05-09 Children's Medical Center Corporation Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
EP2775304A1 (en) * 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
ES2738287T3 (es) 2013-04-09 2020-01-21 Shinji Kagaya Inhibidor de la formación de trampas extracelulares en leucocitos
GB201309180D0 (en) 2013-05-21 2013-07-03 Ucl Business Plc Compounds and Their Uses
BR112015032284A2 (pt) * 2013-06-24 2017-07-25 Dentsply Ih Ab dispositivo médico compreendendo colágeno-vi

Also Published As

Publication number Publication date
US20180271953A1 (en) 2018-09-27
EP3797789A1 (en) 2021-03-31
US20250242000A1 (en) 2025-07-31
EP3247386A4 (en) 2018-10-03
EP3797789B1 (en) 2024-08-21
US20230190886A1 (en) 2023-06-22
WO2016118476A1 (en) 2016-07-28
JP2018503685A (ja) 2018-02-08
EP3247386A1 (en) 2017-11-29
US11400139B2 (en) 2022-08-02

Similar Documents

Publication Publication Date Title
US20250242000A1 (en) Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing
US11819540B2 (en) Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
Weiner et al. The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin
Bellocchio et al. TLRs govern neutrophil activity in aspergillosis
RU2636820C2 (ru) Способы и применения ингибиторов пропротеиновой конвертазы субтилизин кексин типа 9(pcsk9)
US9533002B2 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-β
CN104602682A (zh) 新方法
Han et al. p-Cresyl sulfate promotes the formation of atherosclerotic lesions and induces plaque instability by targeting vascular smooth muscle cells
WO2014180229A1 (zh) 仿生重组高密度脂蛋白在制备预防和治疗阿尔茨海默病药物中的应用
US20230277559A1 (en) Compositions and Methods for the Treatment of Inflammation in Urological Pathology
CN109890364A (zh) 糖尿病肾病的预防和治疗
Yang et al. Liver kinase B1/AMP-activated protein kinase pathway activation attenuated the progression of endotoxemia in the diabetic mice
Ueki et al. D-ribose ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in mice
Bostancı et al. Prevalence of periodontal disease in patients with Familial Mediterranean Fever: a cohort study from central Turkey
US20250049815A1 (en) 25-hydroxycholesterol (25hc), cryab aggregation inhibitor to amelioriate vascular stiffness
WO2024064879A2 (en) Interferon lambda (ifnl) inhibition in intestinal epithelial cells for treating inflammation
US20240279657A1 (en) Compositions and methods for the prevention and treatment of hemoglobinopathies
WO2024097571A1 (en) Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases
Jawale et al. Metabolic ‘De-Programming’of Neutrophils Protects Against Fatal Bloodstream Fungal Infections in Kidney Disease
JP2025537881A (ja) Ｚｌｎ－００５および関連化合物の使用
JP2025540914A (ja) Ｎｌｒｐ１２およびｎｌｒｃ５モジュレーター、ならびにそれらを使用して疾患を調節する方法
WO2024238337A1 (en) Dual-domain peptide for depleting hmgb1 from the circulation via liver hspg system
TW201249436A (en) Use of epigallocatechin-3-gallate for immune regulation
Sormendi Gómez The Oxygen Sensor Hif-Prolyl Hydroxylase-2 (Phd2) Is a prominent regulator of the Neutrophil Inflammatory Response

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210105

EEER Examination request

Effective date: 20210105

FZDE Discontinued

Effective date: 20230321

FZDE Discontinued

Effective date: 20230321